ArticleBMC primary care2025
Why patients fail to seek information on OTC product interactions with a direct-acting oral anticoagulant: perspectives on information-seeking.
Article in BMC primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMany patients taking direct-acting oral anticoagulants (DOACs) also consume over-the-counter (OTC) products (dietary supplements and OTC medications), yet many lack knowledge of potential interactions that may increase or decrease DOAC efficacy and may not seek information about OTC products. The objective of this study was to describe patient attitudes and beliefs that inhibited information seeking about potential apixaban-OTC product interactions.
methodsParticipants included English-, Spanish-, Mandarin-, and Cantonese-speaking adults from two large academic medical centers who reported taking apixaban (a frequently prescribed DOAC) in the past month. Thematic analysis was performed on semi-structured interviews.
resultsSixty patients aged 24-93 years (mean = 65.3; SD = 15.6) were interviewed; 55% were women. Participants took a total of 236 OTC products. Those with potential interactions with apixaban warranting consideration for therapy modification included: ibuprofen (n = 14; 5.9%), aspirin (n = 8; 3.4%), and naproxen (n = 3; 1.3%). Interviews revealed 5 major themes related to a lack of information-seeking about OTC products: (1) patients lack awareness of the potential for interactions; (2) patients believe that OTC products are safe and/or regulated (largely because they were familiar with the products, had previously taken them, or assumed that dietary supplements were regulated by the Food and Drug Administration); (3) patients believe that providers are responsible for alerting patients about potential interactions (as patients assumed that providers were aware of their OTC product use); (4) patients had prior knowledge of and/or used OTC products infrequently; and (5) obtaining information can be inconvenient. Inquiries regarding preferred information sources revealed 59 (98.3%) patients most frequently sought or would seek information from physicians and 34 (56.7%) from the internet.
conclusionsPatients taking apixaban raised reasons for not seeking information about potential OTC product interactions that included poor awareness, perceptions regarding the safety of OTC products, and beliefs in provider responsibility for informing them about interactions. Greater patient education is needed regarding the potential for OTC product-DOAC interactions and the regulation of OTC products, particularly dietary supplements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.